In vitro selection and characterization of bacillus anthracis mutants with high-level resistance to ciprofloxacin

Lance B. Price, Amy Vogler, Talima R Pearson, Joseph D. Busch, James M. Schupp, Paul S Keim

Research output: Contribution to journalArticle

72 Citations (Scopus)

Abstract

Mutants of attenuated Bacillus anthracis with high-level ciprofloxacin resistance were isolated using a three-step in vitro selection. Ciprofloxacin MICs were 0.5 μg/ml for first-step mutants, which had one of two gyrA quinolone resistance-determining region (QRDR) mutations. Ciprofloxacin MICs were 8 and 16 μg/ml for second-step mutants, which had one of three parC QRDR mutations. Ciprofloxacin MICs for third-step mutants were 32 and 64 μg/ml. Mutants for which MICs were 64 μg/ml had one of two additional mutations within the gyrA QRDR or one of two mutations within the gyrB QRDR. Mutants for which MICs were 32 μg/ml had no additional target modifications but showed evidence of enhanced ciprofloxacin efflux.

Original languageEnglish (US)
Pages (from-to)2362-2365
Number of pages4
JournalAntimicrobial Agents and Chemotherapy
Volume47
Issue number7
DOIs
StatePublished - Jul 1 2003

Fingerprint

Bacillus anthracis
Ciprofloxacin
Quinolones
Mutation
In Vitro Techniques

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

In vitro selection and characterization of bacillus anthracis mutants with high-level resistance to ciprofloxacin. / Price, Lance B.; Vogler, Amy; Pearson, Talima R; Busch, Joseph D.; Schupp, James M.; Keim, Paul S.

In: Antimicrobial Agents and Chemotherapy, Vol. 47, No. 7, 01.07.2003, p. 2362-2365.

Research output: Contribution to journalArticle

@article{881732642e484b7ea4ff78ba40c82c6a,
title = "In vitro selection and characterization of bacillus anthracis mutants with high-level resistance to ciprofloxacin",
abstract = "Mutants of attenuated Bacillus anthracis with high-level ciprofloxacin resistance were isolated using a three-step in vitro selection. Ciprofloxacin MICs were 0.5 μg/ml for first-step mutants, which had one of two gyrA quinolone resistance-determining region (QRDR) mutations. Ciprofloxacin MICs were 8 and 16 μg/ml for second-step mutants, which had one of three parC QRDR mutations. Ciprofloxacin MICs for third-step mutants were 32 and 64 μg/ml. Mutants for which MICs were 64 μg/ml had one of two additional mutations within the gyrA QRDR or one of two mutations within the gyrB QRDR. Mutants for which MICs were 32 μg/ml had no additional target modifications but showed evidence of enhanced ciprofloxacin efflux.",
author = "Price, {Lance B.} and Amy Vogler and Pearson, {Talima R} and Busch, {Joseph D.} and Schupp, {James M.} and Keim, {Paul S}",
year = "2003",
month = "7",
day = "1",
doi = "10.1128/AAC.47.7.2362-2365.2003",
language = "English (US)",
volume = "47",
pages = "2362--2365",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "7",

}

TY - JOUR

T1 - In vitro selection and characterization of bacillus anthracis mutants with high-level resistance to ciprofloxacin

AU - Price, Lance B.

AU - Vogler, Amy

AU - Pearson, Talima R

AU - Busch, Joseph D.

AU - Schupp, James M.

AU - Keim, Paul S

PY - 2003/7/1

Y1 - 2003/7/1

N2 - Mutants of attenuated Bacillus anthracis with high-level ciprofloxacin resistance were isolated using a three-step in vitro selection. Ciprofloxacin MICs were 0.5 μg/ml for first-step mutants, which had one of two gyrA quinolone resistance-determining region (QRDR) mutations. Ciprofloxacin MICs were 8 and 16 μg/ml for second-step mutants, which had one of three parC QRDR mutations. Ciprofloxacin MICs for third-step mutants were 32 and 64 μg/ml. Mutants for which MICs were 64 μg/ml had one of two additional mutations within the gyrA QRDR or one of two mutations within the gyrB QRDR. Mutants for which MICs were 32 μg/ml had no additional target modifications but showed evidence of enhanced ciprofloxacin efflux.

AB - Mutants of attenuated Bacillus anthracis with high-level ciprofloxacin resistance were isolated using a three-step in vitro selection. Ciprofloxacin MICs were 0.5 μg/ml for first-step mutants, which had one of two gyrA quinolone resistance-determining region (QRDR) mutations. Ciprofloxacin MICs were 8 and 16 μg/ml for second-step mutants, which had one of three parC QRDR mutations. Ciprofloxacin MICs for third-step mutants were 32 and 64 μg/ml. Mutants for which MICs were 64 μg/ml had one of two additional mutations within the gyrA QRDR or one of two mutations within the gyrB QRDR. Mutants for which MICs were 32 μg/ml had no additional target modifications but showed evidence of enhanced ciprofloxacin efflux.

UR - http://www.scopus.com/inward/record.url?scp=0038650918&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038650918&partnerID=8YFLogxK

U2 - 10.1128/AAC.47.7.2362-2365.2003

DO - 10.1128/AAC.47.7.2362-2365.2003

M3 - Article

VL - 47

SP - 2362

EP - 2365

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 7

ER -